# Irregular periods before 40: how ovarian insufficiency is evaluated

FSH, estradiol and menstrual history have different roles in evaluating ovarian insufficiency. Repeat FSH is needed when the diagnosis remains uncertain.

Canonical: https://velri.co/blog/early-menopause-38-estradiol-fsh-biomarkers-provider-reviews
Publisher: Velri (https://velri.co/about)
Published: 2026-06-23
Updated: 2026-09-30
Editorial policy: https://velri.co/editorial-policy

Periods that stop or become persistently irregular before age 40 deserve an evaluation. Premature ovarian insufficiency, or POI, is one possible explanation. The diagnosis combines the menstrual pattern with evidence of reduced ovarian activity, rather than relying on a hormone result alone. [1]

POI refers to loss of ovarian activity before 40. Current guidance uses “early menopause” for cessation of ovarian function at ages 40 to 44. These terms describe different age groups. [1]

## FSH is part of the assessment

Follicle-stimulating hormone, or FSH, is made by the pituitary gland and helps regulate ovarian function. Its level is interpreted with symptoms, menstrual history and other findings. [2]

The current international POI guideline combines several months of absent or irregular periods with an elevated FSH result. A repeat FSH test is recommended when there is diagnostic uncertainty, rather than being required for every diagnosis. Testing for suspected POI does not have to occur on one particular menstrual-cycle day. [1]

## Estradiol and AMH answer different questions

Low estradiol can support the finding of reduced ovarian activity when considered alongside elevated FSH. The guideline does not recommend diagnosing POI from estradiol alone. [1]

Anti-Müllerian hormone, or AMH, is also not the primary diagnostic test for POI. It may help clarify uncertainty when FSH results are inconclusive, but the result still needs the clinical context. [1]

## Other explanations need consideration

Pregnancy needs to be excluded when periods stop. Medicines can also affect menstrual patterns and hormone results, so the provider needs a complete medication history before interpreting testing. [1]

If POI is diagnosed, the conversation extends to possible causes, symptoms, bone health and reproductive goals. The cause is not always identifiable. Ovarian activity can sometimes occur in nonsurgical POI, which is one reason the condition should not be described simply as permanent menopause. [1]

## Sources
[1] Evidence-based guideline: Premature Ovarian Insufficiency  (2025) | American Society for Reproductive Medicine | ASRM. https://www.asrm.org/practice-guidance/practice-committee-documents/evidence-based-guideline-premature-ovarian-insufficiency--2024/
[2] Follicle-Stimulating Hormone (FSH) Levels Test: MedlinePlus Medical Test. https://medlineplus.gov/lab-tests/follicle-stimulating-hormone-fsh-levels-test/

## About this information
General health information, not personal medical advice, diagnosis or treatment. A prescription is required and is never guaranteed.
Velri is a brand operated by Velri Management LLC, a Nevada limited liability company. Velri is a non-clinical technology and administrative services company. Velri does not provide medical advice, diagnosis, treatment, or pharmacy services, and does not direct the clinical judgment of any provider.
All medical consultations and prescriptions are provided directly by independent provider groups (Online Medical Care, P.C.; TMD of Kansas, P.A.; TMD of Texas, P.A.; and TMD of CA, PC), by a provider licensed in your state. Velri does not employ providers. A prescription is issued only if a provider determines it is clinically appropriate in their independent medical judgment.
All prescription products are dispensed by independent, licensed pharmacies. Velri does not own, operate, or control any pharmacy and does not dispense medication. You may opt out of using a given provider group or pharmacy at any time.
Compounded medications are not reviewed or approved by the FDA for safety, effectiveness, or quality. Compounded products are not equivalent to or interchangeable with any FDA-approved brand-name drug. Availability varies by state.
Velri is cash-pay. We do not bill Medicare, Medicaid, or commercial insurance. Refunds and order problems are addressed in the Terms of Use; your rights under applicable law are not limited. State availability and clinical eligibility apply.
Velri and telehealth are not for medical emergencies. If you are experiencing an emergency, call 911.
These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.
Care is available to eligible adults 18 and older in 47 states and D.C., United States only.
Notice of Privacy Practices: https://velri.co/privacy/notice-of-privacy-practices
Terms: https://velri.co/legal/terms
Provider group or pharmacy opt-out help: https://velri.co/contact and https://velri.co/standards#trust-support